DirectCare AI
AI-powered telehealth platform for chronic care management and virtual specialty programs like TRT and GLP-1.
Website: https://www.directcare.ai/
Cover Block
PUBLIC
| Name | DirectCare AI |
| Tagline | AI-powered telehealth platform for chronic care management and virtual specialty programs like TRT and GLP-1. |
| Headquarters | South Florida |
| Founded | 2025 |
| Business Model | B2C |
| Industry | Healthtech |
| Technology | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
Note: Stage, funding label, and total disclosed funding are not publicly available.
Links
PUBLIC
- Website: https://www.directcare.ai/
- LinkedIn: https://www.linkedin.com/company/directcareai/
- Facebook: https://www.facebook.com/directcareaiold/
Executive Summary
PUBLIC DirectCare AI is a newly launched telehealth platform that merits investor attention for its dual-pronged approach to a high-growth, fragmented market, combining direct-to-consumer virtual clinics with institutional software for AI-powered remote patient monitoring [Perplexity Sonar Pro Brief]. The company, founded in 2025 by Scott Hozebin, targets two distinct revenue streams: a B2C offering for popular specialty care programs like GLP-1 weight loss and hormone replacement therapy, and a B2B platform enabling clinics to deploy and manage chronic care programs [DirectCare AI].
Its differentiation rests on positioning between pure telehealth facilitators and clinical workflow tools, using AI to personalize treatment and automate monitoring tasks for providers, a claim highlighted in a third-party review of its TRT service [Newswire, March 2025]. The founding team is led by a solo founder whose public profile includes membership in the Forbes Technology Council and concurrent roles as a growth advisor and managing director at other firms, suggesting a network-oriented, commercial background rather than deep clinical or technical operating experience [Forbes Councils, 2024].
Capitalization is not publicly disclosed; the absence of confirmed funding rounds or named institutional investors indicates the company is likely in a pre-seed or bootstrapped phase, relying on founder capital or undisclosed angel backing. Over the next 12-18 months, key signals to monitor will be the announcement of a first institutional round, the disclosure of specific healthcare provider or employer customers for its B2B platform, and any regulatory developments affecting the prescription and delivery of compounded medications central to its DTC model.
Data Accuracy: YELLOW -- Core product claims are sourced from company materials and a single review article; founder role is confirmed by Forbes Councils. Funding, traction, and team details lack independent verification.
Taxonomy Snapshot
| Axis | Classification |
|---|---|
| Business Model | B2C |
| Industry / Vertical | Healthtech |
| Technology Type | AI / Machine Learning |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Solo Founder |
Company Overview
PUBLIC DirectCare AI presents as a new entrant in the telehealth and remote patient monitoring space, founded in 2025 and headquartered in South Florida [DirectCare AI]. The company's public narrative positions it as a response to infrastructure gaps in primary care, aiming to modernize clinical workflows with AI automation [LinkedIn, May 2024]. The founding story and any specific early milestones are not detailed in public sources, leaving the chronology of its development from concept to launch unclear. The company's legal entity structure is not disclosed on its website or in state filings accessible via public search.
The company is led by a solo founder, Scott Hozebin, who serves as Chief Executive Officer [Forbes Councils, 2024]. Hozebin's concurrent roles as a Managing Director at MetaEquity Partners and an advisor at Better Health suggest a background in business development and growth strategy, though his direct operational experience in scaling a telehealth platform is not publicly documented [Forbes Business Development Council, 2025]. Key operational milestones appear limited to the launch of its direct-to-consumer virtual clinics for specialty programs like GLP-1 and TRT, and the promotion of its B2B remote patient monitoring solution to healthcare institutions, as described on its website and in a 2025 review article [Newswire, March 2025] [DirectCare AI].
Data Accuracy: YELLOW -- Company website and founder profile provide basic details; founding year and solo founder status are consistent across sources. No independent verification of milestones or legal structure.
Product and Technology
MIXED
DirectCare AI's product is a dual-sided telehealth platform, serving both individual consumers and healthcare institutions through a shared foundation of AI-enabled remote monitoring and virtual clinician access. For patients, the offering is a direct-to-consumer virtual clinic focused on high-demand specialty programs, including GLP-1 weight loss, testosterone replacement therapy (TRT), hormone replacement therapy (HRT), and hair loss treatments [DirectCare AI]. The patient journey, as described on the company's website, follows a standard telehealth model: an online medical history intake, a consultation with a US-licensed physician, and the delivery of personalized medication, such as compounded semaglutide or enclomiphene, directly to the patient's home [DirectCare AI]. The platform's AI component is positioned as providing personalized guidance and support throughout this process.
For healthcare providers, the platform is marketed as a turnkey solution to implement Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) programs. The company claims its system enables remote patient enrollment, integrates with connected health devices, and uses AI to help clinical staff track patient vitals and identify individuals who may need earlier intervention [Perplexity Sonar Pro Brief]. This institutional-facing product is aimed at clinics and physician groups seeking to modernize care delivery and address infrastructure gaps without building their own technology stack [LinkedIn, February 2025].
The technology stack is not explicitly detailed in public materials. However, the company's active recruitment for a data analyst intern [PUBLIC] and a marketing intern [PUBLIC] suggests an early-stage, lean operational build. The core technological differentiator appears to be the application of AI for care personalization and clinical workflow support, rather than a proprietary medical device or novel diagnostic model. All treatment protocols are supervised by licensed physicians, and medication is sourced through compounding pharmacies, indicating the platform's role is primarily care coordination and delivery logistics.
Data Accuracy: YELLOW -- Product features are described consistently across the company's website and a single third-party review. The AI and RPM capabilities are claimed by the company but lack independent technical validation or detailed case studies.
Market Research
PUBLIC
The market for AI-enhanced telehealth and remote patient monitoring is expanding as providers seek scalable ways to manage chronic populations and capitalize on high-demand specialty treatments. Demand is driven by a persistent shortage of primary care capacity, rising prevalence of chronic conditions, and growing consumer comfort with virtual care models for both general wellness and specific therapeutic areas like weight management and hormone health.
Third-party market sizing specific to DirectCare AI's combined model is not publicly available. However, analogous public reports illustrate the scale of the segments the company targets. The US remote patient monitoring market was valued at approximately $1.2 billion in 2023 and is projected to grow at a compound annual rate of over 18% through 2030, according to a Grand View Research report cited by multiple industry analyses [Grand View Research, 2024]. The direct-to-consumer telehealth market for weight loss and hormone therapies is a more nascent but rapidly growing subset, with the global GLP-1 agonist market alone forecast to exceed $100 billion by 2031 [Research and Markets, 2024].
Key demand tailwinds are well-documented. The shift toward value-based care reimbursement creates financial incentives for providers to adopt chronic care management and RPM tools. Simultaneously, consumer demand for convenient, discrete access to treatments like GLP-1s and TRT has created a new category of cash-pay virtual clinics. Regulatory forces are a double-edged sword; while the permanent expansion of telehealth reimbursement post-pandemic is a tailwind, the space for compounded medications and direct-to-consumer prescribing remains under scrutiny, introducing compliance risk [FDA, 2025].
Adjacent and substitute markets include traditional in-person specialty clinics, pharmacy benefit manager (PBM)-led medication programs, and standalone digital health apps for condition management. The company's institutional offering also competes with the consulting and implementation services of larger healthcare IT vendors, suggesting its total addressable market is a slice of broader digital transformation spend.
| Metric | Value |
|---|---|
| US Remote Patient Monitoring Market 2023 | 1.2 $B |
| Projected CAGR 2024-2030 | 18 % |
| Global GLP-1 Agonist Market 2031 | 100 $B |
The projected growth rates in core segments suggest a receptive environment, though the lack of a proprietary TAM estimate makes it difficult to gauge the company's specific market share ambition. The dual B2C and B2B model attempts to capture value from two distinct but related demand pools.
Data Accuracy: YELLOW -- Market sizing is based on analogous third-party reports for broad categories, not company-specific analysis. Tailwinds and regulatory context are cited from public industry coverage.
Competitive Landscape
MIXED
DirectCare AI enters a crowded telehealth market by attempting to serve two distinct customer bases with a single platform, a positioning that creates both opportunity and exposure.
| Company | Positioning | Stage / Funding | Notable Differentiator | Source |
|---|---|---|---|---|
| Centivo | Health plan administrator focused on self-funded employers, offering a primary-care centered model. | Raised $51M in 2021; backed by investors like Bain Capital Ventures. | Employer-focused, not D2C; built as an alternative health plan with defined provider networks. | [Crunchbase, 2021] |
| iMedX | Provider of healthcare documentation and revenue cycle management software and services. | Privately held; historical funding not disclosed. | Focus on clinical documentation and coding for hospitals/physicians, not patient-facing telehealth. | [iMedX] |
| CommonSpirit | One of the largest non-profit health systems in the US, with extensive hospital and clinic networks. | Not applicable (health system). | Vertically integrated care delivery with massive existing patient base and physical infrastructure. | [CommonSpirit] |
The competitive map reveals DirectCare AI is not competing head-to-head with any single entity across its entire scope. Instead, it faces distinct rivals in each segment. In the direct-to-consumer men's and women's health clinic space, it competes with a dense field of venture-backed telehealth providers like Hims & Hers, Ro, and Everly Health, which have established brands and significant marketing budgets [PUBLIC]. For its institutional Remote Patient Monitoring (RPM) and Chronic Care Management (CCM) offerings, the competition shifts to healthcare IT vendors such as Health Recovery Solutions, Vivify Health, and Biofourmis, which sell software and services to health systems and physician groups [PRIVATE]. Adjacent substitutes include the in-house digital health teams of large provider organizations like CommonSpirit, which can develop similar capabilities internally, and traditional specialty clinics that offer in-person TRT and weight management services.
The company's primary defensible edge today is its integrated two-sided model, which is less common than pure-play B2C or B2B telehealth platforms. This allows for potential operational synergies, such as applying learnings from direct patient interactions to its institutional software. A secondary edge may stem from its focus on specific, high-demand therapeutic areas (GLP-1, TRT) where it can develop concentrated expertise. However, this edge is perishable. It depends on execution speed and capital, as larger, well-funded competitors in either segment could easily extend into the other, nullifying the integration advantage. Without disclosed funding, the durability of this position is uncertain.
DirectCare AI is most exposed in distribution. In the D2C segment, it lacks the brand recognition and customer acquisition machinery of incumbents who have spent years and hundreds of millions on marketing. In the B2B segment, selling to healthcare institutions requires long sales cycles, compliance expertise, and integration capabilities that are capital- and talent-intensive to build. A named competitor's specific advantage is clear: a company like Hims & Hers owns the D2C consumer mindshare and has a public market capitalization to fund continued growth, while a company like Biofourmis has deep, validated partnerships with large health systems and payers that DirectCare AI cannot yet claim [PRIVATE].
The most plausible 18-month scenario is one of increased segmentation pressure. If consumer demand for GLP-1 and hormone therapies remains strong but reimbursement tightens, the winner will be the company with the most efficient patient acquisition cost and a clear path to profitability, which currently favors the scaled D2C incumbents. Conversely, if healthcare provider investment in RPM accelerates, the loser will be platforms that cannot demonstrate proven clinical outcomes and smooth EHR integrations, a risk for any early-stage entrant like DirectCare AI. The company's fate likely hinges on whether it can secure institutional capital to deepen one side of its business before competitors encroach on the other.
Data Accuracy: YELLOW -- Competitor identification is public, but analysis of segment dynamics and relative advantages relies on inferred market structure.
Opportunity
PUBLIC
DirectCare AI’s opportunity hinges on capturing a meaningful share of the high-margin, high-growth virtual specialty care market by building a dual-channel platform that serves both direct-to-consumer patients and institutional healthcare providers.
The headline opportunity is to become the dominant vertically integrated platform for AI-managed chronic and lifestyle care. The company’s early positioning across GLP-1, hormone therapies, and remote patient monitoring suggests a strategy to own the entire patient journey for specific, recurring conditions. This outcome is reachable because the company is already operating in the space, with a live platform offering physician-supervised treatment plans and medication delivery [DirectCare AI]. The cited evidence shows a functional product and a clear market wedge: compliant, AI-enhanced telehealth that differentiates from supplement sellers and generic telemedicine [Newswire, March 2025]. The path is not purely aspirational; it requires scaling a model that is already in market.
Growth scenarios outline concrete paths to scale. The table below details two plausible, high-impact trajectories.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Institutional RPM as a wedge | Healthcare systems adopt DirectCare AI’s remote patient monitoring (RPM) and chronic care management (CCM) platform as a turnkey solution, creating a sticky B2B revenue base. | A formal partnership with a named regional health system or large physician group, announced and cited in trade press. | The company already markets an “Institutions” solution aimed at clinics seeking to modernize care and close infrastructure gaps [DirectCare AI]. The regulatory push for value-based care creates strong demand for such tools. |
| Category consolidation in men’s/women’s health | DirectCare AI acquires or out-competes smaller, less-compliant telehealth clinics in the TRT/GLP-1 space, becoming a trusted national brand. | Securing a growth equity round specifically earmarked for marketing and M&A, reported by a financial news outlet. | The market is fragmented with many direct-to-consumer players. A 2025 review positioned DirectCare AI as a compliant, physician-supervised alternative, indicating a quality wedge exists [Newswire, March 2025]. |
What compounding looks like is a data-driven clinical flywheel. Each patient enrolled in a chronic care or specialty program generates longitudinal health data. This dataset, processed by the company’s AI, could improve personalization of treatment protocols and early intervention alerts. Better outcomes would, in turn, improve patient retention and provider satisfaction. For the institutional side, successful deployments with initial clinic partners would generate case studies and referenceable customers, lowering the cost of sales for similar subsequent clients. The flywheel’s first turn is suggested by the company’s claim that its AI tools help clinicians track vitals and intervene earlier [DirectCare AI], though evidence of measurable outcome improvements is not yet public.
The size of the win can be framed by looking at comparable transactions and valuations in adjacent telehealth sectors. For instance, the acquisition of a direct-to-consumer men’s health platform or a remote monitoring company could provide a valuation benchmark. If the “Category consolidation” scenario plays out, capturing a single-digit percentage of the estimated multi-billion dollar US telehealth market for weight management and hormone therapy could translate into a company valued in the hundreds of millions of dollars (scenario, not a forecast). A more conservative, near-term win based on the institutional scenario might align with the valuation of niche RPM software providers, which have seen acquisitions in the $50M to $200M range. The absence of a specific, cited TAM for its sub-segments makes a precise valuation difficult, but the scale of the underlying healthcare spend suggests the opportunity is substantial.
Data Accuracy: YELLOW -- Opportunity analysis is based on company positioning and one third-party review; market size and comparable valuation benchmarks are not independently sourced.
Sources
PUBLIC
[Perplexity Sonar Pro Brief] DirectCare AI Brief | https://www.perplexity.ai/
[DirectCare AI] DirectCare AI | AI-Powered Health Guidance & Remote Monitoring | https://www.directcare.ai/
[Newswire, March 2025] DirectCare AI Review: Best Remote TRT Service in 2025 | https://www.newswire.com/news/directcare-ai-review-best-remote-trt-service-in-2025-22617005
[Forbes Councils, 2024] Scott Hozebin | Chief Executive Officer (CEO) - DirectCare AI | https://councils.forbes.com/profile/Scott-Hozebin-Chief-Executive-Officer-CEO-DirectCare-AI/02c9c5d0-a6ea-4d62-b6a2-a2723e9d1148
[LinkedIn, May 2024] How DirectCare AI is transforming primary care with AI. | https://www.linkedin.com/posts/directcareai_healthcare-ai-directcareai-activity-7375886451147837440-aCTv
[Forbes Business Development Council, 2025] Scott Hozebin - Forbes Business Development Council | https://www.forbes.com/councils/forbesbusinessdevelopmentcouncil/people/scotthozebin/
[LinkedIn, February 2025] Closing the healthcare infrastructure gap with DirectCare AI. | https://www.linkedin.com/posts/directcareai_healthcare-digitalhealth-chroniccare-activity-7447259407073202176-uwsd
[Grand View Research, 2024] US Remote Patient Monitoring Market Report | https://www.grandviewresearch.com/
[Research and Markets, 2024] Global GLP-1 Agonist Market Report | https://www.researchandmarkets.com/
[FDA, 2025] FDA Statements on Compounded Medications | https://www.fda.gov/
[Crunchbase, 2021] Centivo Funding Round | https://www.crunchbase.com/
[iMedX] iMedX Corporate Website | https://www.imedx.com/
[CommonSpirit] CommonSpirit Health Corporate Website | https://www.commonspirit.org/
Articles about DirectCare AI
- DirectCare AI Is Building a Clinic for GLP-1 and Testosterone — The telehealth startup is betting its AI can manage the chronic conditions that primary care often can't.